CASCADIA

This study is no longer open to enrollment and our project is complete.

CASCADIA is a five year study of population level vaccine effectiveness in the Pacific Northwest the Chu lab is conducting in partnership with the University of Washington School of Medicine and Seattle Children’s Hospital in Seattle, WA, along with the Kaiser Permanente Center for Health Research (CHR) in Portland, Oregon. CASCADIA is launching in the summer of 2022 and aims to enroll 3,500 children and adults to assess how well COVID-19 vaccines protect children aged 5 to 18 years. The study will also look at infections among all participants—young and old, vaccinated and unvaccinated—to better understand the role variants of the virus have in infection and the effect of risk factors, such as age, health status, and socio-demographic characteristics. Beyond COVID-19, testing will be done for flu and other respiratory viruses.  

More information is available on the CASCADIA website. 

Publications

Feldstein LR, Ruffin J, Wiegand RE, Borkowf CB, James-Gist J, Babu TM, Briggs-Hagen M, Chappell J, Chu HY, Englund JA, Kuntz JL, Lauring AS, Lo N, Carone M, Lockwood C, Martin ET, Midgley CM, Monto AS, Naleway AL, Ogilvie T, Saydah S, Schmidt MA, Schmitz JE, Smith N, Sohn I, Starita L, Talbot HK, Weil AA, Grijalva CG. Effectiveness of mRNA COVID-19 vaccines and hybrid immunity in preventing SARS-CoV-2 infection and symptomatic COVID-19 among adults in the United States. J Infect Dis. 2025 Jan 8;. doi: 10.1093/infdis/jiaf007. [Epub ahead of print] PubMed PMID: 39774936.

 

Feldstein LR, Ruffin J, Wiegand R, Grant L, Babu TM, Briggs-Hagen M, Burgess JL, Caban-Martinez AJ, Chu HY, Ellingson KD, Englund JA, Hegmann KT, Jeddy Z, Kuntz J, Lauring AS, Lutrick K, Martin ET, Mathenge C, Meece J, Midgley CM, Monto AS, Naleway AL, Newes-Adeyi G, Odame-Bamfo L, Olsho LE, Phillips AL, Rai RP, Saydah S, Smith N, Tyner H, Vaughan M, Weil AA, Yoon SK, Britton A, Gaglani M. Protection from COVID-19 vaccination and prior SARS-CoV-2 infection among children aged 6 months - 4 years, United States, September 2022-April 2023. J Pediatric Infect Dis Soc. 2024 Dec 5;. doi: 10.1093/jpids/piae121. [Epub ahead of print] PubMed PMID: 39656907.

Feldstein LR, Britton A, Grant L, Wiegand R, Ruffin J, Babu TM, Briggs Hagen M, Burgess JL, Caban-Martinez AJ, Chu HY, Ellingson KD, Englund JA, Hegmann KT, Jeddy Z, Lauring AS, Lutrick K, Martin ET, Mathenge C, Meece J, Midgley CM, Monto AS, Newes-Adeyi G, Odame-Bamfo L, Olsho LEW, Phillips AL, Rai RP, Saydah S, Smith N, Steinhardt L, Tyner H, Vandermeer M, Vaughan M, Yoon SK, Gaglani M, Naleway AL. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years. JAMA. 2024 Feb 6;331(5):408-416. doi: 10.1001/jama.2023.27022. PubMed PMID: 38319331; PubMed Central PMCID: PMC10848053.

Babu TM, Feldstein LR, Saydah S, Acker Z, Boisvert CL, Briggs-Hagen M, Carone M, Casto A, Cox SN, Ehmen B, Englund JA, Fortmann SP, Frivold CJ, Groom H, Han PD, Kuntz JL, Lockwood T, Midgley CM, Mularski RA, Ogilvie T, Reich SL, Schmidt MA, Smith N, Starita L, Stone J, Vandermeer M, Weil AA, Wolf CR, Chu HY, Naleway AL. CASCADIA: a prospective community-based study protocol for assessing SARS-CoV-2 vaccine effectiveness in children and adults using a remote nasal swab collection and web-based survey design. BMJ Open. 2023 Jul 14.